Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase â…¡ Clinical Trial
To observe the differences in the efficacy of Combination followed by maintenance chemotherapy versus CDK4/6 inhibitor combined with endocrine therapy in HR low expression /HER2 negative advanced breast cancer, and to provide new evidence for the best treatment of HR low expression /HER2 negative advanced breast cancer, and to explore the efficacy and safety of combined/maintenance chemotherapy.
Advanced Breast Cancer|Treatment|HR Low/HER2 Negative
DRUG: Experimental: chemotheyapy|DRUG: Active Comparator: endocrine therapy
ORR by investigator using RECIST Guideline (Version 1.1), ORR was defined as percentage of participants with best (confirmed) overall response (BOR) of either CR or PR assessed by the investigator according to RECIST version 1.1, 6 weeks
PFS, PFS was defined as the time from first dose to first documented disease progression (PD) or death from any cause, whichever occurred first, up to 1.5 years|Adverse events, Proportion of participants experienced adverse events during the study period, up to 1.5 years|OS, OS was defined as the time from first dose to death for any cause, up to 3 years
To observe the differences in the efficacy of Combination followed by maintenance chemotherapy versus CDK4/6 inhibitor combined with endocrine therapy in HR low expression /HER2 negative advanced breast cancer, and to provide new evidence for the best treatment of HR low expression /HER2 negative advanced breast cancer, and to explore the efficacy and safety of combined/maintenance chemotherapy.